Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Zinc finger protein 224 (ZNF224)
- Target
- ZNF224
- Molecular classification
- Transcription factor, Zinc finger protein, Krüppel-associated box (KRAB) domain protein
01
Overview
Zinc finger protein 224 (ZNF224) is a Krüppel-associated box (KRAB) domain-containing transcription factor belonging to the C2H2-type zinc finger protein family. ZNF224 primarily acts as a transcriptional repressor, interacting with corepressors such as KAP1 and PRMT5 to silence gene expression, notably of genes like aldolase A and the mitochondrial citrate carrier. Alternative splicing generates isoforms like ZNF255, which differ in subcellular localization and functions. ZNF224 modulates crucial cellular processes—promoting oncogenic traits and apoptosis resistance in several cancer types by downregulating tumor suppressor genes, including p21 and p53, via direct promoter binding and through miRNA-mediated mechanisms (notably miR-663a upregulation). Depending on cellular context and interacting partners, ZNF224 can function as either an oncoprotein or a tumor suppressor
- Other names
- ZNF224BMZF2KOX22ZNF233ZNF255ZNF27BMZF-2Bone marrow zinc finger 2Zinc finger protein 233Zinc finger protein 255Zinc finger protein 27Zinc finger protein KOX22
02
Mechanism of action
Not established for specific drugs. However, repression/activation of gene transcription is the principal mechanism by which this factor impacts cellular phenotypes. Any drug effects would be indirect, downstream of gene regulatory changes
03
Biological functions
Transcriptional repressionTranscriptional co-activation with Wilms’ tumor protein 1 (WT1)Regulation of cell proliferation and apoptosisChromatin remodeling through interactions with corepressor complexesRegulation of glycolytic and mitochondrial gene expression (e.g., aldolase A, mitochondrial citrate carrier)
04
Disease associations
Cancer (including breast, melanoma, bladder, prostate)Oncogenesis (functions as oncoprotein or tumor suppressor depending on context)Inhibition of apoptosis (promotes cancer cell survival via repression of p53 and p21 expression)Bladder carcinogenesis (via DEPDC1A-ZNF224 complex suppressing apoptosis)
05
Safety considerations
Therapeutic targeting could affect broad transcriptional networks, including effects on p53/p21-mediated apoptosis, creating risks for dysregulated cell growth and impaired normal cell cycle control
06
Biomarkers
Increased expression of ZNF224 (protein and/or mRNA) can serve as a marker in certain cancers, such as breast ductal carcinoma, correlating with apoptosis resistance and disease progression
Beyond the preview
Go deeper on Zinc finger protein 224 (ZNF224).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Zinc finger protein 224 (ZNF224).